Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKAB2 | O43741 | 5/20 | 0.44 |
| ▸ | PRKAG1 | P54619 | 5/20 | 0.44 |
| ▸ | PRKAA2 | P54646 | 5/20 | 0.44 |
| ▸ | PRKAA1 | Q13131 | 5/20 | 0.44 |
| ▸ | PRKAG3 | Q9UGI9 | 5/20 | 0.44 |
| ▸ | PRKAG2 | Q9UGJ0 | 5/20 | 0.44 |
| ▸ | PRKAB1 | Q9Y478 | 5/20 | 0.44 |
| ▸ | KRAS | P01116 | 5/20 | 0.41 |
| ▸ | JAK3 | P52333 | 2/20 | 0.40 |
| ▸ | BTK | Q06187 | 4/20 | 0.40 |
| ▸ | LCK | P06239 | 1/20 | 0.40 |
| ▸ | SRC | P12931 | 1/20 | 0.40 |
| ▸ | CDK14 | O94921 | 1/20 | 0.39 |
| ▸ | CCNY | Q8ND76 | 1/20 | 0.39 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.37 |
| ▸ | RBP4 | P02753 | 1/20 | 0.37 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29766081 | 0.85 | FGFR4 (0.51) | KRASJAK3BTKCDK14CCNY | |
| SCHEMBL16636976 | 0.85 | FGFR4 (0.51) | KRASJAK3BTKCDK14CCNY | |
| SCHEMBL16646871 | 0.83 | KRAS (0.51) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL16636897 | 0.80 | KRAS (0.48) | KRAS | |
| SCHEMBL29765798 | 0.80 | KRAS (0.48) | KRAS | |
| SCHEMBL21302112 | 0.78 | MCHR1 (0.45) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL17833927 | 0.75 | GSK3B (0.53) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL21302103 | 0.74 | KRAS (0.46) | KRASBTK | |
| SCHEMBL16646903 | 0.71 | EGFR (0.55) | KRASBTKPAK1 | |
| SCHEMBL22173981 | 0.71 | EPHX2 (0.47) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9840516-B2 | Substituted quinazolines as inhibitors of KRAS G12C | ARAXES PHARMA LLC (US) | 2017-12-12 | — | — | US | disclosed |
| US-20150239900-A1 | INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC | 2015-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150239900-A1 | INHIBITORS OF KRAS G12C | KRAS, NRAS, HRAS | PRKAB2 1396/4885PRKAG1 1104/4885PRKAA2 1348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.